Identification of international classification of functioning, disability and health relevant categories to describe functioning and disability of patients with myasthenia gravis

Disability and Rehabilitation

Volumn 31, Issue 24, 2009, Pages 2041-2046

  Leonardi, Matilde ^a   Raggi, Alberto ^a   Antozzi, Carlo ^b   Confalonieri, Paolo ^b   Maggi, Lorenzo ^b   Cornelio, Ferdinando ^c   Mantegazza, Renato ^b  

^a National Neurological Institute   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Disability; ICF classification; Myasthenia gravis

Indexed keywords

ADULT; ARTICLE; CHECKLIST; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENVIRONMENTAL FACTOR; FEMALE; HEALTH PRACTITIONER; HOUSEHOLD; HUMAN; INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYASTHENIA GRAVIS; PREVALENCE; PRIORITY JOURNAL; SOCIAL WORKER;

ACTIVITIES OF DAILY LIVING; ADULT; DISABILITY EVALUATION; DISABLED PERSONS; FEMALE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MYASTHENIA GRAVIS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 70449111710     PISSN: 09638288     EISSN: 14645165     Source Type: Journal    
DOI: 10.3109/09638280902893634     Document Type: Article

References (29)

1. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest 2006;116:2843-2854.
2. Jaretzki A III, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America. Neurology 2000;55:16-23.
3. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001;357:2122-2128.
4. Palace J, Newsom-Davis J, Lecky B. A randomized doubleblind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998;50:1778-1783.
5. Gronseth GS, Barhon RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology 2000;55:7-15.
6. Mantegazza R, Baggi F, Bernasconi P, Antozzi C, Confalonieri P, Novellino L, Spinelli L, Ferrò MT, Beghi E, Cornelio F. Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in nonthymomatous myasthenia gravis patients: remission after 6 years of follow-up. J Neurol Sci 2003;212:31-36.
7. Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 1988;235:449-453.
8. Sharshar T, Chevret S, Mazighi M, Chillet P, Huberfeld G, Berreotta C, Houfani M, Gajdos P. Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. J Neurol 2000;247: 286-290.
9. Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker- Lipscomb B, Sanders DB. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 2005;64:1968-1970.
10. Meriggioli MN, Sanders DB. Myasthenia gravis: diagnosis. Semin Neurol 2004;24:31-39.
11. Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord 2006;16:459-467.
12. Saperstein DS, Barohn RJ. Management of myasthenia gravis. Semin Neurol 2004;24:41-48.
13. Sieb JP. Myasthenia gravis: emerging new therapy options. Curr Opin Pharmacol 2005;5:303-307.
14. Barohn RJ, Mcintire D, Herbelin L, Wolfe GI, Nations S, Bryan W. Reliability testing of the quantitative myasthenia gravis score. Ann NY Acad Sci 1998;841:769-772.
15. Bedlack RS, Simel DL, Bosworth H, Samsa B, Tucker- Lipscomb B, Sanders DB. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 2006;64:1968-1970.
16. Tindall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a doubleblind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987;316:719-724.
17. Sharshar T, Chevret S, Mazighi M, Chillet P, Huberfeld G, Berreotta C, Houfani M, Gajdos P. Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. J Neurol 2000;247: 286-290.
18. Burns TM, Conaway MR, Cutter GR, Sanders DB, the Muscle Study Group. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve 2008;38:1553-1562.
19. Romani A, Piccolo G, Bergamaschi R, Versino M, Cosi V. A reliability study of impairments and disability scales for myasthenia gravis patients. Funct Neurol 2002;17:137-144.
20. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 1999;52:1487-1489.
21. Vandervelde L, Van den Bergh PY, Goemans N, Thonnard JL. ACTIVLIM: a Rasch-built measure of activity limitations in children and adults with neuromuscular disorders. Neuromuscul Disord 2007;17:459-469.
22. World Health Organization. The international classification of functioning, disability and health: ICF. Geneva: World Health Organization; 2001.
23. Leonardi M, Bickenbach J, Ustun TB, Kostanjek N, Chatterji S, on behalf of the MHADIE Consortium. The definition of disability: what is in a name? Lancet 2006;368:1219-1921.
24. Stucki G, Ewert T, Cieza A. Value and application of the ICF in rehabilitation medicine. Disabil Rehabil 2002;24: 932-938.
25. Ewert T, Grill E, Bartholomeyczik S, Finger M, Mokrusch T, Kostanjsek N, Stucki G. ICF core set for patients with neurological conditions in the acute hospital. Disabil Rehabil 2005;27:367-374.
26. Stier-Jarmer M, Grill E, Ewert T, Bartholomeyczik S, Finger M, Mokrusch T, Kostanjsek N, Stucki G. ICF core set for patients with neurological conditions in early post-acute rehabilitation facilities. Disabil Rehabil 2005;27:389-396.
27. Grill E, Lipp B, Boldt C, Stucki G, Koenig E. Identification of relevant ICF categories by patients with neurological conditions in early post-acute rehabilitation facilities. Disabil Rehabil 2005;27:459-465. (Pubitemid 40711876)
28. Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P, Andreetta F, Simoncini O, Campanella A, Beghi E, Cornelio F. Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci 2003;998:413-423.
29. Leonardi M, Bickenbach J, Raggi A, Sala M, Guzzon P, Valsecchi MR, Fusaro G, Russo E, Francescutti C, Nocentini U, Martinuzzi A. Training on the international classification of functioning, disability and health (ICF): the ICF-DIN Basic and the ICF-DIN advanced course developed by the disability Italian network. J Headache Pain 2005;6:159-164.